Brought to you by 
Metabolex gets $32mm in Series D funding
24 Apr 2007
Executive Summary
Metabolex (drugs to treat diabetes and related metabolic disorders) brought in $32mm via its Series D financing led by MPM BioEquities. Other new investors AllianceBernstein, Deerfield Management, and T. Rowe Price were joined by returning shareholders Alta Partners, Bay City Capital, Biotech Turnaround Fund, Birchmere Ventures, Johnson & Johnson Development Corp., KBC Funds, Lombard Odier Darier Hentsch, Pictet Funds Biotech, Merlin BioMed Group, Novo Ventures, VantagePoint Venture Partners, Venrock Partners, and Versant Ventures. The company will use the proceeds for ongoing development of MBX8025, which is preparing to enter Phase II trials for dyslipidemia, and for preclinical candidates.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Metabolex gets $32mm in Series D funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice